{"name":"Jun Wang","slug":"jun-wang","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"intravenous hydromorphone","genericName":"intravenous hydromorphone","slug":"intravenous-hydromorphone","indication":"Other","status":"marketed"},{"name":"intravenous hydromorphone and dexmedetomidine","genericName":"intravenous hydromorphone and dexmedetomidine","slug":"intravenous-hydromorphone-and-dexmedetomidine","indication":"Other","status":"marketed"},{"name":"intravenous sufentanil","genericName":"intravenous sufentanil","slug":"intravenous-sufentanil","indication":"Other","status":"marketed"},{"name":"intravenous sufentanil and dexmedetomidine","genericName":"intravenous sufentanil and dexmedetomidine","slug":"intravenous-sufentanil-and-dexmedetomidine","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"intravenous hydromorphone","genericName":"intravenous hydromorphone","slug":"intravenous-hydromorphone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intravenous hydromorphone and dexmedetomidine","genericName":"intravenous hydromorphone and dexmedetomidine","slug":"intravenous-hydromorphone-and-dexmedetomidine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intravenous sufentanil","genericName":"intravenous sufentanil","slug":"intravenous-sufentanil","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"intravenous sufentanil and dexmedetomidine","genericName":"intravenous sufentanil and dexmedetomidine","slug":"intravenous-sufentanil-and-dexmedetomidine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5CcnF5ZS1udWNoWDhJb29mU1VYZ0VGRDM4RVdYUFo0b1ZRUWRBY1diODFJUElUSlN2Mm9NZ0lGS3BUbzNyazhrOUZicG1nNm1Qb1NLUmpR?oc=5","date":"2026-03-10","type":"pipeline","source":"Forbes","summary":"Wang Junmin - Forbes","headline":"Wang Junmin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNOU5vd2IzNm1CZFIyT0EzWDR0OVVaazhnMWY2eTJaT3BPTWRZVGVKMEloYVNMb0lmdDhWcUJtWV9sQ2l2eHZqakJfeUJuMmJkVmhiaXNBY0VKVlRNV21NRFR6Ulkyc1JkTXg3Zm8zMlJ6R1l3c0NacFA3ZUNFRzBUMDZ1ZkVkNmVwZUxhWTlSRmpkRGMwZVE?oc=5","date":"2025-11-14","type":"pipeline","source":"Frontiers","summary":"Potential spillover effect of eco-directed pharmaceutical disposal on pro-environmental disinfectant use among Chinese residents - Frontiers","headline":"Potential spillover effect of eco-directed pharmaceutical disposal on pro-environmental disinfectant use among Chinese r","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5CLVRlZVplRXVHVTVnWUpxTUNhWVBjMHFqRjlYQnpPbXROQ1pmXzBiXzlraXpzcDNwWGZFUmd3VWZLT05PdlI2N1d4UTlQUVdyV2prZkZmUmpIODNZMEhJ?oc=5","date":"2025-08-07","type":"trial","source":"Nature","summary":"The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized controlled trial - Nature","headline":"The efficacy and safety of inhaled peptide YKYY017 for COVID-19 patients with mild illness: a phase 2 randomized control","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9JcnBlanNqTmE0MGlTQmtNN2dUNDJ3TlhZN3NPUzVmTFBzNGZIeUVpSXhFVjMzdmdibTVPb3p6R2ZvUDZyc2pyQXU0aHhHSzMyRFM0UTVGOXYwVG1Ndy1Tb3pFbEZ1RUJURzdENEJsRGo5QQ?oc=5","date":"2025-06-17","type":"deal","source":"info.gov.hk","summary":"Public urged not to buy or use topical products containing undeclared controlled ingredients (with photo) - info.gov.hk","headline":"Public urged not to buy or use topical products containing undeclared controlled ingredients (with photo)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBHTXM5YjVVUm1YUG02Nm4tcUhZZ3N5ZHFFSVJ4Q1ZheUwxdzdqUi1SRi1PTTlWOENtbWRsWkJpRDBmbFlxQXFkQUNOdC1iaWVBZDd1dldMQU9wY2JYZl9lMlBfUzhlbTg?oc=5","date":"2025-04-21","type":"pipeline","source":"ACS Publications","summary":"Dual Photoexcited Palladium and Photoredox-Catalyzed Remote C(sp3)–H Acylation of Hydroxyamides - ACS Publications","headline":"Dual Photoexcited Palladium and Photoredox-Catalyzed Remote C(sp3)–H Acylation of Hydroxyamides","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOVEtXb3VZNmVWdW1OZzNrZUQ0TkRCd3U4N3ZiZUxkRGJOWllMMnQtZmdvMjB3eVNndHRhaEZBLTg0NklYODdoMGpXeG1IQmJIajcxck9peG56enV6a3ExZDM5cmVOUWRsSjNoWEdkRnlKSEpJTkxrTzlrVzhpUFNYR2pySU9QYkphSXRXX0hqSFVOYkNH?oc=5","date":"2025-02-07","type":"deal","source":"Bain Capital","summary":"Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation - Bain Capital","headline":"Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5WaG9tQ0kyNHRDZGtlLVZ2ZWgtVjNhNVd0V3NMZDltSkNJd3FaSDlKY2V0a3NKTUhpSGZhcUFUczQ3NTJzTDVadXB2LUx0aVFVekFwZ0hHU3FEdWw2Uk9WdA?oc=5","date":"2024-03-28","type":"pipeline","source":"Science | AAAS","summary":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model - Science | AAAS","headline":"Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBuVExDUVVVSGV6Sks5S2dwdWJMM2hGd3pYb2JHalB2WDQzblpFSFd0d0VSVGtGX3dIMUl2UXY1dXJKUFVTbDNpMnJ2VTRzeEp6eldBYW9FNlNDU0N4VlBLRlNBaElySjdhY200bXQ5RTAxMHpteVp3Zg?oc=5","date":"2022-09-19","type":"pipeline","source":"Rutgers University","summary":"It’s a Matter of When: Getting Ready for “Pathogen X” - Rutgers University","headline":"It’s a Matter of When: Getting Ready for “Pathogen X”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQUV9SampnWENId0ZPTG9QcE0tRGZqa2ZmeVVlRnpFU3B6YnlDM3VFbDhWZWZGMzNoU0xIbTVENmR4Q05sSHpOSU5GRzlZOXE2djJvLUFUT1N0YURULURIZXQ0eFNMODVzQzVPTDlVdkxBN21sZGhNTHZHcnVzSk1mWUFoSW0yaGhEZk9Ndy1aUGJJY0EyQ2hoS0llcldURGdTbS1Hd2RKSVpvU25NT1Rn?oc=5","date":"2021-08-27","type":"trial","source":"Fierce Biotech","summary":"Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials - Fierce Biotech","headline":"Lynk Pharmaceuticals inks $50M series B for 3 early-stage trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5CNWdYTU1rN1ZDYll3eGxxbEJtU3ptVDJNb3p0M0lMYjZNZmJOVGdFNm11NExPNWlWczl5Qkp0UFBHNjM0WVpGT1FCUkV0ZWpqc0JlenVsVnRuOWlIbUhPMERKVGprN2tnOTRhb2xB?oc=5","date":"2020-05-21","type":"pipeline","source":"University of Arizona News","summary":"Pharmacists on the Frontlines of COVID-19 - University of Arizona News","headline":"Pharmacists on the Frontlines of COVID-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOS3k4d2hEbkIzblFsVTFYNXhpMTRrd3hEWEx3WHRoUEJLYjRWVHNweEZnZHJJbTZFdnVZandtb3B3b3hfdnZPdjhxNFlDUlViOXFicE05TUxTb1pGZUE5d0o1M0Zoc2pxTHp0YXFETktsbW81V3NJUWcxRHBuaHdFMg?oc=5","date":"2019-12-15","type":"pipeline","source":"CORDIS","summary":"Scientists develop new antibiotic - CORDIS","headline":"Scientists develop new antibiotic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQbE9GblVheEVlT1A5UGFGNTRWQmtZeEp4V3hmcGlUbEVPakxJTWREU2dyc3ZyZWVTV1A1cWtzVWVOelNxUzI3MHdXVDFzZGQycjNmcHA4cVpMZ2pHNW1UeDdfNmEtSGo5UWtDdGZFeEFqLTEzV3ctcWVkREJBaUktUDNlanpkdlk5bHBRTVdQTGQ4MXVtaGlDcW12dGJTdFV0LVFEcmtQcDI?oc=5","date":"2016-07-17","type":"pipeline","source":"Fierce Pharma","summary":"China's iCarbonX gets $45M as part of growing precision medicine push - Fierce Pharma","headline":"China's iCarbonX gets $45M as part of growing precision medicine push","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}